News >

Pivotal Role Remains With Bone-Targeting Agents in mCRPC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Sep 26, 2017

Dr. Charles J. Ryan from the University of California San Francisco

Charles J. Ryan, MD
Prostate cancer researchers are continuing to explore strategies to optimally integrate bone-targeted agents into patient care.

on Genitourinary Cancers, lectured on the impact of bone-targeting agents in patients with mCRPC. In an interview during the event, he shed light on the evolution of zoledronic acid and denosumab (Xgeva), and the future role of radium-223 as it begins to be studied in combination regimens.

OncLive: How are bone-targeting agents used in the management of advanced prostate cancer?

Ryan: Bone-targeting agents are critically important, and that’s because 90% of men who die from prostate cancer die with boney metastases, and often they die because of the complications of boney metastases. While we continue our research and clinical development of new therapies that target the tumor directly, it’s also critically important to think about the bones and how we can protect them from tumor invasion, and, in fact, reduce the likelihood of the disease killing patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x